A case with a KRASA146P mutation was identified as acquired resistance in the KRASG12C inhibitor; no additional mutations in KRAS were identified as acquired resistance in PDAC, contrasting with NSCLC and CRC acquired resistance [115]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.